Hypermarcas (OTCMKTS:HYPMY – Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $3.96, but opened at $4.1125. Hypermarcas shares last traded at $4.1125, with a volume of 218 shares trading hands.
Wall Street Analyst Weigh In
Separately, Zacks Research raised shares of Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Hypermarcas has a consensus rating of “Buy”.
View Our Latest Stock Analysis on Hypermarcas
Hypermarcas Stock Up 2.4%
Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The company had revenue of $383.13 million during the quarter. Equities research analysts expect that Hypermarcas will post 0.53 earnings per share for the current year.
Hypermarcas Company Profile
Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.
Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.
Featured Stories
- Five stocks we like better than Hypermarcas
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
